Enlivex Therapeutics Ltd. — Director's Dealing 2019

Jul 17, 2019

	Number of	Percentage of
	Ordinary Shares	Ordinary Shares
Major Shareholders as of June 30, 2019	Beneficially Owned	Beneficially Owned
The Company's 5% or Greater Shareholders (other than Directors and Executive Officers)
HBL-Hadasit Bio-Holdings Ltd	1,798,727	17.8%
Michael Hobi	691,310	6.8%
Kretzmer and Associates PLLC	830,973	8.2%
KIP Global Pharma-Ecosystem Private Equity Fund	1,417,950	14.0%
Directors and Executive Officers
Shai Novik, Executive Chairman (1)	882,515	8.6%
Avri Havron, Director (2)	488,356	4.8%
Dror Mevorach (3)	455,591	4.3%
Bernhard Kirschbaum	-	*
Gili Hart, Director (4)	95,192	*
Sangwoo Lee (5)	13,298	*
Hyun-Gyu Lee (5)	13,298	*
Michel Habib (5)	13,298	*
Baruch Halpert (6)	24,412	*
Dr. Shmulik Hess	-	*
Shachar Shlosberger (7)	2,058	*
All directors and executive officers as a group	1,988,018	18.2%

• * Less than 1%.
• (1) Includes 169,289 shares underlying options exercisable within 60 days from April 15, 2019. 132,979 of these options expire in January 2025 and have an exercise price of NIS 2.6853 and 36,310 of these options expire in December 2027 and have an exercise price of NIS 6.2236.
• (2) Includes 53,192 shares underlying options exercisable within 60 days from April 15, 2019, which expire in January 2025 and have an exercise price of NIS 2.6853.
• (3) Includes 455,591 shares underlying options exercisable within 60 days from April 15, 2019. 398,937 of these options expire in January 2025 and have an exercise price of NIS 2.6853, 20,344 of these options expire in March 2027 and have an exercise price of NIS 2.6853, 30,258 of these options expire in December 2027 and have an exercise price of NIS 6.2236 and 6,052 of these options expire in January 2028 with an exercise price of NIS 6.2236.
• (4) Includes 66,490 shares underlying options exercisable within 60 days from April 15, 2019, which expire in January 2025 and have an exercise price of NIS 2.6853.
• (5) Includes 13,298 shares underlying options exercisable within 60 days from April 15, 2019, which expire in December 2027 and have an exercise price of NIS 6.2236.
• (6) Includes 24,412 shares underlying options exercisable within 60 days from April 15, 2019. 13,298 of these options expire in December 2027 and have an exercise price of NIS 6.2236 and 11,114 of these options expire in January 2028 and have exercise price of NIS 6.2236.
• (7) Includes 2,058 shares underlying options exercisable within 60 days from April 15, 2019. 968 of these options expire in April 2026 and have an exercise price of 2.6853,726 of these options expire in March 2027 and have an exercise price of NIS 2.6853, and 364 of these options expire in December 2027 and have an exercise price of NIS 6.2236.